Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 257

1.

Improving the cost-effectiveness of cardiovascular disease prevention in Australia: a modelling study.

Cobiac LJ, Magnus A, Barendregt JJ, Carter R, Vos T.

BMC Public Health. 2012 Jun 1;12:398. doi: 10.1186/1471-2458-12-398.

2.
4.

National guidelines for the management of absolute cardiovascular disease risk.

Usherwood T.

Med J Aust. 2013 Aug 19;199(4):243-4. No abstract available.

PMID:
23984778
5.

Moderately Elevated Blood Pressure: A Systematic Review [Internet].

Swedish Council on Health Technology Assessment.

Stockholm: Swedish Council on Health Technology Assessment (SBU); 2004 Oct.

6.

Asymptomatic peripheral arterial disease: is pharmacological prevention of cardiovascular risk cost-effective?

Sigvant B, Henriksson M, Lundin F, Wahlberg E.

Eur J Cardiovasc Prev Rehabil. 2011 Apr;18(2):254-61. doi: 10.1177/1741826710389368. Epub 2011 Jan 28.

PMID:
21450673
7.

Moderately Elevated Blood Pressure: A Systematic Review [Internet].

Swedish Council on Health Technology Assessment.

Stockholm: Swedish Council on Health Technology Assessment (SBU); 2008 Sep.

8.
9.

Patterns of prescription antihypertensive drug utilization and adherence to treatment guidelines in the city of Novi Sad.

Tomas A, Tomić Z, Milijasević B, Ban M, Horvat O, Vukmirović S, Sabo A.

Vojnosanit Pregl. 2016 Jun;73(6):531-7.

PMID:
27498444
10.

A systematic review and economic evaluation of statins for the prevention of coronary events.

Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, Yeo W, Payne N.

Health Technol Assess. 2007 Apr;11(14):1-160, iii-iv. Review.

11.

Cost-effectiveness of medical primary prevention strategies to reduce absolute risk of cardiovascular disease in Tanzania: a Markov modelling study.

Ngalesoni FN, Ruhago GM, Mori AT, Robberstad B, Norheim OF.

BMC Health Serv Res. 2016 May 17;16:185. doi: 10.1186/s12913-016-1409-3.

12.

Which interventions offer best value for money in primary prevention of cardiovascular disease?

Cobiac LJ, Magnus A, Lim S, Barendregt JJ, Carter R, Vos T.

PLoS One. 2012;7(7):e41842. doi: 10.1371/journal.pone.0041842. Epub 2012 Jul 23.

13.

Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease.

Pandya A, Sy S, Cho S, Weinstein MC, Gaziano TA.

JAMA. 2015 Jul 14;314(2):142-50. doi: 10.1001/jama.2015.6822. Erratum in: JAMA. 2015 Oct 20;314(15):1647.

14.

Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey.

Yusuf S, Islam S, Chow CK, Rangarajan S, Dagenais G, Diaz R, Gupta R, Kelishadi R, Iqbal R, Avezum A, Kruger A, Kutty R, Lanas F, Lisheng L, Wei L, Lopez-Jaramillo P, Oguz A, Rahman O, Swidan H, Yusoff K, Zatonski W, Rosengren A, Teo KK; Prospective Urban Rural Epidemiology (PURE) Study Investigators.

Lancet. 2011 Oct 1;378(9798):1231-43. doi: 10.1016/S0140-6736(11)61215-4. Epub 2011 Aug 26.

PMID:
21872920
15.

[Pharmaco-economic aspects of the treatment of hypertension].

Delporte JP, Rorive G.

Rev Med Liege. 1998 May;53(5):259-64. French.

PMID:
9689879
17.
18.

Cost-effectiveness of prescribing statins according to pharmaceutical benefits scheme criteria.

Lim SS, Vos T, Peeters A, Liew D, McNeil JJ.

Med J Aust. 2001 Nov 5;175(9):459-64.

PMID:
11758073
19.
20.

Cost-effectiveness of statins for primary prevention in patients newly diagnosed with type 2 diabetes in the Netherlands.

de Vries FM, Denig P, Visser ST, Hak E, Postma MJ.

Value Health. 2014 Mar;17(2):223-30. doi: 10.1016/j.jval.2013.12.010.

Supplemental Content

Support Center